United BioSource (UBC) has acquired Evidinno Outcomes Research, adding outcomes research, evidence synthesis, and health economics and outcomes research (HEOR) depth to UBC’s evidence generation platform as biopharma sponsors face rising demands for regulatory- and payer-ready data.
Evidinno, headquartered in Vancouver, focuses on real-world evidence (RWE), epidemiology, evidence synthesis, and advanced statistical and economic analysis. UBC said the deal strengthens its ability to support late-stage and post-approval research programs aimed at demonstrating safety, effectiveness, and long-term value, while helping sponsors navigate patient access and reimbursement pathways.
UBC positions its evidence development work around modernized study designs and execution supported by data acquisition technology. With Evidinno now part of the organization, UBC expects to expand its capacity to deliver decision-grade outputs used in health technology assessment (HTA), market access, and medical affairs planning.
Evidinno brings a team of epidemiologists, health economists, and research scientists with experience producing HTA- and regulatory-grade evidence. The firm’s offerings include AI-enabled, expert-led literature reviews, comparative effectiveness research, network meta-analyses, health economic modeling, HTA dossier development, and research consulting across the product lifecycle.
Under the transaction, Evidinno will operate as a wholly owned subsidiary of UBC. The combined organization plans to offer an integrated service set spanning clinical development through post-approval, with an emphasis on generating evidence that can inform regulators, payers, clinicians, and other stakeholders.
Support: Fairmount Partners served as exclusive financial advisor to Evidinno.
KEY QUOTES
“Evidinno’s scientific rigor and technology enabled- workflows deepen our ability to curate fit-for-purpose evidence and health economic and outcomes insights for our clients. Together, we will transform the evidence value chain and help sponsors answer important questions on the safety and effectiveness of treatments for patients.”
Aaron Berger, SVP Evidence Development Solutions, UBC
“Joining UBC marks an important step in expanding the reach and influence of Evidinno’s scientific and methodological expertise. By combining our HTA- and regulatory-grade evidence synthesis solutions, real-world research, and economic modeling capabilities with UBC’s global platform, we are well positioned to deliver robust, decision-ready evidence that supports sponsors and improves outcomes for patients world-wide.”
Dr. Mir Sohail Fazeli, MD, PhD, Chief Executive Officer of Evidinno
